Luteolin Effects on Cancer Cell Proliferation and Apoptosis

Luteolin is a plant-derived flavonoid abundant in fruits, vegetables and medicinal herbs. It has attracted considerable interest for its capacity to inhibit cancer cell proliferation and to induce programmed cell death across a spectrum of tumour types. In vitro and in vivo studies demonstrate that luteolin attenuates mitogenic signalling pathways—such as PI3K/Akt, MAPK and Notch—thereby enforcing cell cycle arrest at G₁ or G₂/M checkpoints. Concurrently, it promotes apoptosis through activation of intrinsic and extrinsic caspase cascades, upregulation of pro-apoptotic proteins (for example Bax and p21) and suppression of anti-apoptotic factors (such as Bcl-2). Luteolin also modulates oxidative stress by elevating reactive oxygen species in malignant cells, sensitising mitochondria to apoptotic stimuli. Beyond direct cytotoxicity, luteolin interferes with tumour microenvironment processes—angiogenesis, metastasis and inflammation—by downregulating VEGF, MMPs and pro-inflammatory cytokines. Despite its promise, clinical translation is hindered by poor water solubility and limited bioavailability. Recent efforts focus on nanoformulations and delivery systems to enhance tissue targeting and therapeutic index. Collectively, these findings underline luteolin’s potential as an adjuvant in cancer therapy, offering a multi-modal approach to restraining tumour growth and overcoming resistance to conventional treatments.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Luteolin Effects on Cancer Cell Proliferation and Apoptosis publication trend

The graph below shows the total number of articles in luteolin effects on cancer cell proliferation and apoptosis across all publications each year (not limited to Nature Index journals).

Technical terms

Flavonoid: A class of polyphenolic plant compounds with diverse biological activities, including antioxidant and anticancer effects.

Apoptosis: Programmed cell death characterised by caspase activation, DNA fragmentation and membrane blebbing.

Cell cycle arrest: The interruption of cell division at defined checkpoints (G₁, S or G₂/M) to prevent proliferation of damaged cells.

Bioavailability: The proportion of an administered compound that reaches systemic circulation and target tissues in active form.

Nanoformulation: A delivery system that utilises nanoparticles to improve solubility, stability and targeted delivery of therapeutic agents.

References

1. Recent Developments in Luteolin-Loaded Nanoformulations for Enhanced Anti-Carcinogenic Activities: Insights from In Vitro and In Vivo Studies. Sci (2024).
2. Luteolin, a flavonoid, as an anticancer agent: A review. Biomedicine & Pharmacotherapy (2019).
3. Anti-Inflammatory and Active Biological Properties of the Plant-Derived Bioactive Compounds Luteolin and Luteolin 7-Glucoside. Nutrients (2022).
4. Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Experimental & Molecular Medicine (2019).